AstraZeneca - SELL - Questionable Earnings Quality
AstraZeneca's earnings are increasingly dependent on disposal profits and questionable core earnings adjustements. The share are very highly valued on a more conservative assessment of Profits. SELL
AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Baden Hill has a team of 9 institutional salesmen and analysts operating under the Northland Capital Partners regulatory umbrella. The sales team cover the UK and European stock markets whilst the analysts cover support services, clean tech and equity income. The equity income product has a particular focus on cash flow and accounting quality. The team is also offers capital rasing services and have been involved in a number of succesful flotations and secondary capital raises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.